AstraZeneca PLC (AZN)vsTheravance Biopharma Inc (TBPH)
AZN
AstraZeneca PLC
$158.75
-0.16%
HEALTHCARE · Cap: $263.09B
TBPH
Theravance Biopharma Inc
$16.92
0.00%
HEALTHCARE · Cap: $874.34M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 55802% more annual revenue ($61.37B vs $109.78M). TBPH leads profitability with a 104.3% profit margin vs 17.0%. TBPH trades at a lower P/E of 7.6x. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
TBPH
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+19.3%
Fair Value
$196.68
Current Price
$158.75
$37.93 discount
Margin of Safety
+72.5%
Fair Value
$70.89
Current Price
$16.92
$53.97 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 39 in profit
Keeps 104 of every $100 in revenue as profit
Conservative balance sheet, low leverage
15.0% revenue growth
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Distress zone — elevated risk
Operating margin of -33.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : TBPH
The strongest argument for TBPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 104.3% and operating margin at -33.1%. Revenue growth of 15.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : TBPH
The primary concerns for TBPH are EPS Growth, Market Cap, Altman Z-Score.
Key Dynamics to Monitor
TBPH carries more volatility with a beta of 0.25 — expect wider price swings.
TBPH is growing revenue faster at 15.0% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (60/100 vs 49/100), backed by strong 17.0% margins. TBPH offers better value entry with a 72.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Theravance Biopharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?